Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zimberelimab + anlotinib
- Development stage
- Unknown
- Lead developer
- Guangzhou Gloria Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Zimberelimab + anlotinib is an investigational combination therapy being evaluated for the treatment of various solid tumors, most notably non-small cell lung cancer (NSCLC). Zimberelimab is a fully human IgG4 monoclonal antibody designed to bind to the programmed cell death protein 1 (PD-1) receptor on T-cells, preventing its interaction with ligands PD-L1 and PD-L2 to restore anti-tumor immunity. Anlotinib is an orally administered, multi-target small molecule tyrosine kinase inhibitor that potently inhibits vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptors (PDGFRα/β), and c-Kit. By combining these two agents, the regimen aims to simultaneously inhibit tumor angiogenesis and overcome immune evasion, potentially providing synergistic clinical benefit. The combination is being developed through collaborations involving Guangzhou Gloria Biosciences and Chia Tai Tianqing Pharmaceutical Group, with clinical trials often led by institutions such as Fuzhou First Hospital.
- Brand names
- YuinitFukanghua
- Other names
- zimberelimab and anlotinibanlotinib plus zimberelimab
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on zimberelimab + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zimberelimab + anlotinib.